

Polycaprolactone efficient for nasolabial fold treatment

January 15 2015



(HealthDay)—For patients with nasolabial folds (NLFs), treatment with a novel biostimulatory polycaprolactone (PCL)-based dermal filler is associated with improved long-lasting efficacy compared with nonanimal stabilized hyaluronic acid (NASHA)-based fillers. This finding was published online Jan. 6 in the *Journal of Cosmetic Dermatology*.

Hassan Galadari, M.D., from the United Arab Emirates University in Al Ain, and colleagues conducted a randomized split-face study to compare a novel PCL-based dermal filler with a NASHA-based dermal filler in 40 patients. The authors compared the safety, efficacy, and duration of cosmetic correction for the treatment of NLFs.



The researchers found that compared with NAHSA-based filler, NLFs treated with the PCL-based dermal filler showed statistically significant improvements on the Wrinkle Severity Rating Scale and greater improvements on the Global Aesthetic Improvement Scale at six, nine, and 12 months post-treatment. The products were found to be equivalent in terms of safety and tolerability.

"Our results suggest that PCL-based dermal fillers offer longer-lasting performance over NASHA-based dermal fillers in NLFs <u>treatment</u>," the authors write.

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Polycaprolactone efficient for nasolabial fold treatment (2015, January 15) retrieved 9 January 2023 from https://medicalxpress.com/news/2015-01-polycaprolactone-efficient-nasolabial-treatment.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.